Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms

Corcept Therapeutics has delivered very strong long term share price gains over the past five years, yet its latest valuation checks lean more cautious, leaving investors weighing a powerful performance track record against a weak overall value score.

• Corcept Therapeutics is up about 346.1% over five years, which puts the recent share price in the context of a very strong run already behind it.
• Progress with cortisol modulating drugs, including Lifyorli and the resubmitted relacorilant application, can support expectations for future revenue, while patent disputes around Korlym and regulatory uncertainty for relacorilant may limit how much investors are willing to pay for that growth.
• Corcept Therapeutics currently passes only 1 out of 6 valuation checks, which points to a stock that does not screen as a clear bargain on the broader measures.

The issue now is whether Corcept Therapeutics' share price after this run still offers enough value for the risks tied to its pipeline and legal challenges.

Find out why Corcept Therapeutics' 27.7% return over the last year is lagging behind its peers.

Is Corcept Therapeutics Still Cheap on Sales?

P/S is often a useful cross check for a company like Corcept Therapeutics that is focused on commercialising therapies and where revenue trends tend to be watched closely. Corcept Therapeutics currently trades on a P/S of 12.6x, compared with around 6.1x for the broader Pharmaceuticals industry and 10.6x across its direct peers, so the stock sits at a clear premium to both wider and closer comparators.

On this framework, the tailored fair P/S ratio for Corcept Therapeutics is 17.8x. This takes into account its margins, market position and risk profile. The present 12.6x multiple is below what this model suggests investors might typically pay for this kind of business, which points to a stock that screens as undervalued on sales even after the recent optimism around Lifyorli and updated revenue guidance.

Overall, Corcept Therapeutics appears undervalued on the P/S multiple when set against its modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Corcept Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Corcept Therapeutics build on the valuation question above by explaining what growth, margin and earnings paths would need to occur for the stock to be worth materially more or less than today's price, and they are available on the company's Community page. Each narrative links a fair value to a specific mix of potential catalysts and risks for Corcept Therapeutics, so you can see over time which storyline is reflected in the numbers.

Community views on Corcept Therapeutics are sharply split, with one camp focused on pipeline upside and another worried about execution and regulatory risk.

Bull case: 25% undervalued

"Advancement of miricorilant in MASH and dazucorilant in ALS, both addressing large unmet need populations where early data show compelling signals, offers additional late stage pipeline shots on goal..."

Read the full Bull Case to see why Corcept Therapeutics could be undervalued

Bear case: 81% overvalued

"Net income has declined materially despite strong top line growth, with third quarter 2025 revenue rising to $207.6 million while net income fell to $19.7 million compared to $47.2 million last year..."

Read the full Bear Case to see why Corcept Therapeutics could be overvalued

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Corcept Therapeutics screens as undervalued on its tailored P/S multiple, even after a very strong five year return, yet its broader valuation checks remain weak. That mix suggests the stock is not a straightforward bargain, but rather a case where one model sees upside while the overall profile looks more cautious.

The crux for investors is whether the current premium to industry and peers is justified by Corcept Therapeutics' pipeline execution and resolution of legal and regulatory risks, or whether those same risks explain why the wider valuation score stays low.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com